TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease of more than 5 years~* Subthalamic nucleus stimulation~* Gait disorders impeding moderately to severely the activities of daily living~* gait disorders including freezing of gait~* able to walk without physical assistance~Exclusion Criteria:~* Dementia (MMSE \< 27 et score de Mattis \< 130)~* Requiring dopatherapie modification~* Requiring subthalamic stimulation parameters adaptation~* Psychiatric disorders: hallucinations, unstable thymic disorders, psychosis)~* Cardiac disorders: dysrhythmia or unstable arterial hypertension~* Unstable or severe medical illness~* intolerance or contraindication to methylphenidate

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- methylphenidate (Type: ACTIVE_COMPARATOR): methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
- placebo (Type: PLACEBO_COMPARATOR): tablets of placebo 3 time a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, \>=18 years of age, with locally advanced breast cancer.~Exclusion Criteria:~* previous therapy for any invasive malignancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF (Type: EXPERIMENTAL): Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m\^2), IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m\^2, IV; methotrexate 40 mg/m\^2, IV; and 5-fluorouracil 600 mg/m\^2, IV, on Day 1 of Cycles 8 through 10.
- HER-2+ Doxorubicin/Paclitaxel/CMF (Type: ACTIVE_COMPARATOR): Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
- HER-2- Doxorubicin/Paclitaxel/CMF (Type: ACTIVE_COMPARATOR): Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan for Treatment of COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Confirmed diagnosis of COVID-19 by PCR test~* Hospitalization for COVID-19~* Illness symptoms beginning 4 days or less prior to randomization~Exclusion Criteria:~* Admitted to ICU prior to randomization~* Illness symptoms beginning more than 4 days prior to randomization~* Pregnancy~* Breast feeding~* Major hypersensibility to angiotensin receptor blockers (ARBs)~* Systolic blood pressure \< 100mmHg~* Potassium greater than 5.5 mEq/L~* AST and/or ALT \> 3 times the upper limit of normal~* Serum creatinine higher than 3 mg/dL~* Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TELMISARTAN (Type: EXPERIMENTAL): Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
- CONTROL (Type: NO_INTERVENTION): Patients in this group will receive standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age \>= 18 years~* 2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled~* SSc disease onset (defined by first non-Raynaud symptom) within 7 years~* SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung \>= 10%~* FVC \>= 40% of predicted normal~* Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal~Exclusion criteria:~* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) \>1.5 x ULN~* Bilirubin \>1.5 x ULN~* Creatinine clearance \<30 mL/min~* Airway obstruction (pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1)/FVC \<0.7)~* Other clinically significant pulmonary abnormalities~* Significant Pulmonary Hypertension (PH)~* Cardiovascular diseases~* More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring hospitalization or severe other ulcers~* Bleeding risk (such as predisposition to bleeding, fibrinolysis, full-dose anticoagulation, high dose antiplatelet therapy, history of hemorrhagic central nervous system (CNS) event within last year~* international normalised ratio (INR) \>2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \>1.5 x ULN)~* History of thrombotic event within last year~* Clinical signs of malabsorption or needing parenteral nutrition~* Previous treatment with nintedanib or pirfenidone~* Treatment with prednisone \>10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate~* Unstable background therapy with either mycophenolate mofetil or methotrexate~* Previous or planned hematopoietic stem cell transplantation~* Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nintedanib (Type: EXPERIMENTAL): patient receives capsules containing nintedanib twice a day
- Placebo (Type: PLACEBO_COMPARATOR): patient receives capsules identical to those containing active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* no variation of body weight \> 5 kg over the last 3 mo BMI within 20-25 Age between 20-30~Exclusion Criteria:~* gustatory impairment following a prescribed diet or using medications that might interfere with taste perception food allergies smokers

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- PROP taste sensitivity (Type: None): PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven unresectable MPM of biphasic or sarcomatoid histology~* Naïve to chemotherapy or immunotherapy~* ECOG PS 0-1~* Expected survival of at least 3 months~* Age 18 years or over (there is no upper age limit)~* Measurable disease by modified RECIST criteria for MPM for local pleural disease and RECIST 1.1 criteria for metastatic lesions~* Written (signed and dated) informed consent and must be capable of co-operating with treatment and follow up~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Radiotherapy (except for palliative reasons) in the previous two weeks before study treatment~* History of unstable cardiac disease~* Ongoing toxic manifestations of previous treatments~* Symptomatic brain or spinal cord metastases (patients must be stable for \> 1 month post radiotherapy or surgery)~* Major thoracic or abdominal surgery from which the patient has not yet recovered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: ADI-PEG 20 plus Pem Platinum (Type: EXPERIMENTAL): Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~ADI-PEG 20 plus Pem Platinum: Investigational Drug in combination approved standard of care treatment for this indication
- Drug: Placebo plus Pem Platinum (Type: PLACEBO_COMPARATOR): Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous~Placebo plus Pem Platinum: Placebo in combination approved standard of care treatment for this indication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is aged ≥ 28 years.~* Subject is Caucasian.~* Subject is healthy, as judged by the Investigator.~* Subject has smoked at least 10 commercially available non-menthol CCs per day (no brand restrictions) at least for the last 6 weeks prior to the screening visit and admission.~* Subject has smoked at least for the last 10 years.~* Subject does not plan to quit smoking in the next 6 months.~Exclusion Criteria:~* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).~* Subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2) or cytochrome P450 2A6 (CYP2A6) activity.~* Female subject is pregnant or breast feeding.~* Female subject does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 28 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CHTP 1.2 (Type: EXPERIMENTAL): Ad libitum use of the CHTP 1.2
- CC (Type: ACTIVE_COMPARATOR): Ad libitum use of subject's own preferred non-menthol brand of CC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV uninfected~* Acceptable methods of contraception for females of reproductive potential~* Good general health~* Signed written inform consent~Exclusion Criteria:~* Risk to be infected by HIV virus~* Uveitis, chronic lyme disease, active syphilis, active mycobacterial diseases or sarcoidosis~* Autoimmune disease or immunodeficiency~* Medical history of food allergy, Lyell's or Steven Johnson's disease, unstable asthma~* Active, generalized eczema or chronic urticaria~* Blood products within 2 months prior to first study vaccine administration~* HIV vaccines in prior HIV vaccine trial or participation in an immunomodulator study~* Vaccines within 30 days prior to first study vaccine administration~* Pregnant~* Long-term immunosuppressive or immunomodulator medications or within 6 months to first study vaccine administration~* Blood transfusion within 6 months to first study vaccine administration~* Treated with extracted pituitary hormones

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PD1-CD19-CART in Patients With r/r B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have the capacity to give informed consent;~2. ALL patients with the age between 18 and 70 years old;~3. Expected survival \>3 moths;~4. With no severe heart and lung disease;~5. Previously confirmed diagnosis as CD19+ NHL within 6 months;~6. Hematological index as following, white blood cell (WBC)≥1.5×10\^9/L，absolute neutrophil count (ANC) ≥0.8×10\^9/L, Platelet count≥50×109/L, Hemoglobin (Hgb) ≥ 90mg/L, lymphocyte count≥ 0.4×10\^9/L；~7. Blood biochemical index as no more than 1.5\* ULN, including total bilirubin (TBIL), transglutaminase (AST), alanine aminotransferase (AST), Creatinine (SCr), Urea in patients with no tumor metastasis in liver and kidney; Blood biochemical index no more than 5\* ULN in patients with tumor metastasis in liver and kidney;~8. With a stable cardiac function, the left ventricular ejection fraction (LVEF) ≥ 55%;~9. Virological tests were negative for EBV, CMV, HIV, TP and HCV; a negative HBV DNA test is acceptable if HBsAg is positive;~10. ECOG \<2;~11. Relapsed or refractory (r/r) NHL including, Diffuse large B cell lymphoma(DLBCL, NOS), stage Ⅲ-Ⅳ;Primary mediastinal large B-cell lymphoma (PMBL), stage Ⅲ-Ⅳ; High grade B-cell lymphoma (HGBL), stage Ⅲ-Ⅳ; Mantle cell lymphoma (MCL), stage Ⅲ-Ⅳ; follicular lymphoma (FL), stage Ⅲ-Ⅳ and with aggression. r/r NHL defined as following, demonstrate disease that persists or relapse after achieving complete response (CR) after \> 2 cycles of standard chemotherapy, or relapse after autologous hematopoietic stem cell transplantation (auto-HSCT), or not achieving CR after auto-HSCT.~Exclusion Criteria:~1. Pregnant or lactating women;~2. With a pregnancy plan in the next 2 years;~3. Prior treatment of anti-GVHD therapy;~4. Acceptance of allogeneic stem cell transplant (ASCT);~5. Isolated extramedullary relapse of ALL;~6. Severe mental disorders, active autoimmune diseases, active infectious diseases, severe cardiovascular diseases;~7. Partial prothrombin time or activated partial thromboplastin time or international standardized ratio \> 1.5\*ULN without anticoagulant treatment;~8. History of other type of maligant tumors;~9. Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PD1-CD19-CART (Type: EXPERIMENTAL): Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of PD1-CD19-CART will be infused on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed non-resectable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastro-esophageal junction;~* tumor samples scored as 3+ on immunohistochemistry or FISH (Fluorescence in situ Hybridization) positive (HER2:CEP17 ratio ≥2);~* measurable disease;~* treated by trastuzumab, platin (cisplatine or oxaliplatine), fluoropyrimidine (5-FU or capecitabine) +/- taxanes (docetaxel or paclitaxel),~* as first-line therapy for advanced gastric cancer.~Exclusion Criteria:~* previous chemotherapy by taxane for metastatic disease,~* previous anti-HER2 therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S group (Type: None): platin-5FU + trastuzumab
- T group (Type: None): taxanes + platin-5FU + trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months~* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB~Exclusion Criteria:~* Overactive Bladder caused by neurological condition~* Patient has predominance of stress incontinence~* History or evidence of pelvic or urological abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- onabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
- placebo/onabotulinumtoxinA (Type: OTHER): Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - Active, but clinically stable, plaque psoriasis involving greater than or equal to 10% of the body surface area - A minimum PASI score of 10 obtained during the screening period Exclusion Criteria: - Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit - Evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of an investigational product on psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obese children and adolescents (aged 2-16 years old)~Exclusion Criteria:~* Chronic diseases~* Hypothyroidism~* Medication

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- obese (Type: None): obese subjects according to International Obesity Task Force criteria
- lean (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete